<DOC>
	<DOC>NCT00115973</DOC>
	<brief_summary>This trial is conducted in the United States of America (USA). This is an in-patient trial investigating stepwise dose increase in a period of up to 3-weeks followed by a 10-week out-patient maintenance period. A telephone contact visit is scheduled as a follow-up for the final clinic visit. A subject's participation in this trial would be expected to be up to 16 weeks.</brief_summary>
	<brief_title>A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 2 diabetes diagnosis at least 2 years ago Body Mass Index (BMI): 2640 kg/m^2 (both inclusive) HbA1c: 7.510% (both inclusive) FPG values at least 140 mg/dl (7.8 mmol/l) Use of drugs, which may interfere with the interpretation of trial results or are known to cause clinically relevant interference with insulin action or glucose utilization (steroids or nonspecific betablockers) Current addiction to alcohol or substances of abuse or positive results on urine screen for drug and alcohol use Known or suspected allergy to trial products or related products</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pump</keyword>
	<keyword>Diabetes</keyword>
</DOC>